Kim Kelderman
2021
In 2021, Kim Kelderman earned a total compensation of $3.9M as President, Diagnostics and Genomics at Bio-Techne, a 79% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $908,102 |
|---|---|
| Option Awards | $2,079,987 |
| Salary | $530,000 |
| Stock Awards | $359,839 |
| Other | $8,389 |
| Total | $3,886,317 |
Kelderman received $2.1M in option awards, accounting for 54% of the total pay in 2021.
Kelderman also received $908.1K in non-equity incentive plan, $530K in salary, $359.8K in stock awards and $8.4K in other compensation.
Rankings
In 2021, Kim Kelderman's compensation ranked 3,444th out of 12,397 executives tracked by ExecPay. In other words, Kelderman earned more than 72.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,444 out of 12,397 | 72nd |
Division Manufacturing | 1,405 out of 5,492 | 74th |
Major group Chemicals And Allied Products | 567 out of 2,367 | 76th |
Industry group Drugs | 505 out of 2,090 | 76th |
Industry Biological Products, Except Diagnostic Substances | 134 out of 452 | 70th |
Source: SEC filing on September 14, 2022.
Kelderman's colleagues
We found four more compensation records of executives who worked with Kim Kelderman at Bio-Techne in 2021.